Ocugen is trading at $0.84, with a -5.13% change during the October 14 session amid sector and broader-market pressure.
- Ocugen announced an OCU400 licensing agreement for the Middle East and North Africa; no negative company-specific catalyst has been confirmed, and the agreement does not explain the decline.
- Biotech shares weakened, with XBI down 2.01%.
- Major U.S. indexes were also lower amid hotter-than-expected inflation and rate concerns.